Transactions
Jun. 18, 2002
NEW JERSEY DRUG FIRM CLOSES FIRST FUNDING
On May 23 ESP Pharma Inc. closed its first round of funding, which brought in $28 million for the Flanders, N.J., company. The lead investors were Domain Associates, Apax Partners and New Enterprise Associates.
The lead investors were Domain Associates, Apax Partners and New Enterprise Associates.
ESP Pharma buys specialty drugs to develop further in medical trials. Its signature product is Cardene IV, which is used to treat hypertension.
General counsel Anthony Rascio handled the deal in-house for ESP.
Roseland, N.J.-based Lowenstein Sandler represented ESP Pharma. Partner Peter Ehrenberg and of-counsel Jeffrey Shapiro handled the deal.
Los Angeles partner Michael Sanders and San Francisco associate Dale Freeman of Oakland's Crosby Heafey Roach & May represented the investors.
Stefanie Knapp
For reprint rights or to order a copy of your photo:
Email
Jeremy_Ellis@dailyjournal.com
for prices.
Direct dial: 213-229-5424
Send a letter to the editor:
Email: letters@dailyjournal.com